- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00066781
Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
A Phase II Study Of Gemcitabine (GEMZAR) And Irinotecan (CPT-11) In Previously Untreated Patients With Measurable Disease With Unknown Primary Carcinoma
RATIONALE: Drugs used in chemotherapy such as gemcitabine and irinotecan use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving gemcitabine together with irinotecan works in treating patients with cancer of unknown primary origin.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Determine the response rate in patients with carcinoma of unknown primary when treated with gemcitabine and irinotecan.
- Determine the adverse event profile and tolerability of this regimen, based on the presence or absence of the UGT1A1*28 polymorphism, in these patients. (Cohort I closed to accrual 11/17/05)
- Determine the adverse event profile and tolerability of this regimen. (Cohort II)
Secondary
- Determine the time to progression and overall survival of patients treated with this regimen.
- Correlate patterns of immunohistochemical staining with response in patients treated with this regimen.
- Correlate variation in multiple different genes, whose protein products are involved in the uptake, metabolism, and distribution of these drugs, with clinical outcomes, in terms of response and toxicity, in these patients.
- Determine primary origin of cancer of unknown primary samples by completing a 92-gene RT-PCR cancer classification assay.
- Determine whether the 92-gene assay results are correlated with clinical response to gemcitabine and irinotecan.
OUTLINE:
- Cohort I (closed to accrual 11/17/05): Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Irinotecan dose may be escalated or de-escalated after course 1 depending on toxicity. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
- Cohort II: Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Iowa
-
Mason City, Iowa, United States, 50401
- Mercy Cancer Center at Mercy Medical Center - North Iowa
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Cancer Center
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68510
- Cancer Resource Center - Lincoln
-
Omaha, Nebraska, United States, 68106
- CCOP - Missouri Valley Cancer Consortium
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed carcinoma of undetermined origin, with any of the following light microscopic diagnoses:
Adenocarcinoma
- Poorly differentiated non-small cell carcinoma
- Poorly differentiated squamous cell carcinoma
Primary site not revealed by the following diagnostic tests:
- Complete history and physical
- Complete blood count and chemistries
- Chest x-ray and/or CT scan
- Abdominal CT scan
- Directed evaluation of symptomatic areas
- Mammogram in women
- Colonoscopy in patients with liver metastases to exclude a colon primary
Hematoxylin and eosin (H&E) staining OR immunostaining if H&E results are unclear, including all of the following:
- Keratin or epithelial membrane antigen
- S-100 or HMB45
- LCA (CD45)
- Chromogranin or synaptophysin
- Thyroid transcription factor 1
- Measurable disease
Patients with any of the following conditions are not eligible:
- Neuroendocrine tumors
- Women with axillary node involvement only
- Women with adenocarcinoma of the peritoneum
- Carcinoma involving only 1 site, with resectable tumor at that site
- Squamous cell carcinoma limited to cervical, supraclavicular, or inguinal lymph nodes
- Men with poorly differentiated mediastinal or retroperitoneal tumor with stains suggestive of germ cell origin or serum tumor markers (AFP/HCG)
- Men with prominent blastic bony metastases or markedly elevated prostate-specific antigen, suggesting prostate origin
- Must be willing to provide blood and tissue samples
- No brain or meningeal involvement
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-2
Life expectancy
- At least 12 weeks
Hematopoietic
- Granulocyte count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic
Bilirubin must meet 1 of the following criteria:
- Less than or equal to upper limit of normal (ULN) and no UGT1A1 genotyping is required
- Greater than ULN but less than 2 times ULN and UGT1A1 for 6/7 genotype or 7/7 genotype patients
- Alkaline phosphatase no greater than 3 times ULN
- AST no greater than 3 times ULN (5 times ULN if liver metastases are present)
Renal
- Creatinine no greater than 2.0 times ULN
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other invasive malignancy within the past 5 years
- No other severe concurrent disease that would make the patient inappropriate for the study in the judgment of the investigator
- No uncontrolled infection
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No concurrent biologic agents
- No concurrent filgrastim (G-CSF)
Chemotherapy
- No prior chemotherapy
- No other concurrent chemotherapy
Endocrine therapy
- Not specified
Radiotherapy
- No prior radiotherapy to more than 25% of the bone marrow
- No concurrent radiotherapy
Surgery
- More than 4 weeks since prior major surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort I (closed to accrual 11/17/05)
Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Irinotecan dose may be escalated or de-escalated after course 1 depending on toxicity.
Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
|
Given IV
Given IV
|
Experimental: Cohort II
Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1, 8, and 15.
Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
|
Given IV
Given IV
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Confirmed Response Rate (Partial or Complete Response for 2 Consecutive Evaluations at Least 4 Weeks Apart) as Measured by RECIST Criteria
Time Frame: Up to 2 years
|
The primary endpoint is confirmed response rate.
If measurable disease is present, a confirmed tumor response is defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart.
All registered patients meeting the eligibility criteria that have signed a consent form and have begun treatment will be evaluable for response.
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: Up to 2 years
|
Overall survival time is defined as the time from registration to death due> to any cause.
The distribution of survival time will be estimated using> the method of Kaplan-Meier .
Overall survival will be calculated for> all evaluable patients combined and by group (ie.
for patients with or> without the UGT1A1*28 polymorphism).
|
Up to 2 years
|
Time to Disease Progression
Time Frame: Up to 2 years
|
Time to disease progression is defined as the time from registration to documentation of disease progression.
If a patient dies without a documentation of disease progression, the patient will be considered to have had tumor progression at the time of their death unless there is sufficient documented evidence to conclude no progression occurred prior to death.
If the patient is declared to be a major treatment violation, the patient will be censored on the date the treatment violation was declared to have occurred.
In the case of a patient starting treatment and then never returning for any evaluations, the patient will be censored for progression on day 1 post-registration.
The distribution of time to progression will be estimated using the method of Kaplan-Meier.
Time to disease progression will be calculated for all evaluable patients combined and by group (ie.
for patients with or without the UGT1A1*28 polymorphism).
|
Up to 2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Matthew P. Goetz, MD, Mayo Clinic
Publications and helpful links
General Publications
- Holtan SG, Foster NR, Erlichman CE, et al.: Gemcitabine (G) and irinotecan (CPT-11) as first-line therapy for carcinoma (ca) of unknown primary (CUP): An NCCTG phase II trial. [Abstract] J Clin Oncol 26 (Suppl 15): A-13525, 2008.
- Holtan SG, Steen PD, Foster NR, Erlichman C, Medeiros F, Ames MM, Safgren SL, Graham DL, Behrens RJ, Goetz MP. Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial. PLoS One. 2012;7(7):e39285. doi: 10.1371/journal.pone.0039285. Epub 2012 Jul 17.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplastic Processes
- Neoplasm Metastasis
- Carcinoma
- Neoplasms, Unknown Primary
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Gemcitabine
- Irinotecan
Other Study ID Numbers
- NCCTG-N004E
- NCI-2011-01592 (Registry Identifier: CTRP (Clinical Trials Reporting System))
- CDR0000318830 (Registry Identifier: PDQ (Physician Data Query))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma of Unknown Primary
-
Rigshospitalet, DenmarkThe Novo Nordic FoundationCompletedUnknown Primary Cancer | Cancer of Unknown Primary Site | Unknown Primary, Squamous Cell CarcinomaDenmark
-
AHS Cancer Control AlbertaTom Baker Cancer CentreActive, not recruitingCarcinoma of Unknown PrimaryCanada
-
University of Michigan Rogel Cancer CenterEli Lilly and CompanyTerminatedCarcinoma of Unknown PrimaryUnited States
-
European Organisation for Research and Treatment...NCIC Clinical Trials Group; Radiation Therapy Oncology Group; Danish Head and...CompletedCarcinoma of Unknown PrimaryUnited States, Canada, Switzerland, Belgium, Netherlands, Denmark
-
Samsung Medical CenterUnknownCarcinoma of Unknown PrimaryKorea, Republic of
-
OnxeoSpectrum Pharmaceuticals, IncCompletedCarcinoma of Unknown PrimaryUnited States, Germany, France, Denmark
-
University of Medicine and Dentistry of New JerseyNational Cancer Institute (NCI)WithdrawnCarcinoma of Unknown PrimaryUnited States
-
Academisch Ziekenhuis MaastrichtUnknownCarcinoma of Unknown PrimaryNetherlands
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedCarcinoma of Unknown Primary OriginUnited States
-
The Christie NHS Foundation TrustUnknownCarcinoma of Unknown PrimaryUnited Kingdom
Clinical Trials on gemcitabine hydrochloride
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedStage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer AJCC v8 | Stage III Renal Pelvis and Ureter Cancer AJCC v8 | Stage IV Renal Pelvis and Ureter Cancer AJCC v8 | Stage 0a Renal Pelvis and Ureter Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Beth ChristianCompletedRecurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma | Adult Nodular Lymphocyte Predominant Hodgkin LymphomaUnited States
-
National Cancer Institute (NCI)CompletedStage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial CancerUnited States
-
NCIC Clinical Trials GroupCompleted
-
National Cancer Institute (NCI)CompletedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditionsUnited States
-
OSI PharmaceuticalsNational Cancer Institute (NCI)CompletedPancreatic Cancer | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
NCIC Clinical Trials GroupCompleted
-
Institute of Liver and Biliary Sciences, IndiaRecruiting